HC Wainwright Issues Pessimistic Forecast for ABEO Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Research analysts at HC Wainwright cut their Q2 2025 EPS estimates for Abeona Therapeutics in a note issued to investors on Monday, May 19th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.39) per share for the quarter, down from their prior forecast of ($0.37). HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics' Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.80) EPS, Q1 2026 earnings at $0.05 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.16 EPS and FY2026 earnings at $0.37 EPS.

ABEO has been the topic of several other reports. Stifel Nicolaus lowered their price target on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Oppenheimer began coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 target price on the stock. Wall Street Zen downgraded Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 15th. Finally, Alliance Global Partners reaffirmed a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $18.50.

Abeona Therapeutics Stock Down 2.4%

Shares of NASDAQ:ABEO traded down $0.16 during trading on Wednesday, reaching $6.42. 957,198 shares of the stock traded hands, compared to its average volume of 619,860. The stock has a market cap of $328.43 million, a P/E ratio of -2.39 and a beta of 1.68. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The stock has a 50-day moving average of $5.29 and a two-hundred day moving average of $5.55. Abeona Therapeutics has a 52-week low of $3.93 and a 52-week high of $7.32.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.11.

Insider Buying and Selling at Abeona Therapeutics

In other Abeona Therapeutics news, Director Mark Alvino sold 8,000 shares of the business's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $5.68, for a total transaction of $45,440.00. Following the completion of the sale, the director now directly owns 92,435 shares in the company, valued at approximately $525,030.80. The trade was a 7.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vishwas Seshadri sold 25,000 shares of the stock in a transaction on Monday, March 31st. The shares were sold at an average price of $4.78, for a total value of $119,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,355,322 shares of the company's stock, valued at approximately $6,478,439.16. This represents a 1.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 6.90% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its holdings in Abeona Therapeutics by 74.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company's stock worth $424,000 after purchasing an additional 28,606 shares during the period. Wellington Management Group LLP purchased a new stake in Abeona Therapeutics in the 4th quarter valued at $520,000. Trexquant Investment LP purchased a new position in shares of Abeona Therapeutics during the fourth quarter worth about $382,000. Adage Capital Partners GP L.L.C. increased its holdings in shares of Abeona Therapeutics by 20.1% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company's stock valued at $21,736,000 after purchasing an additional 652,366 shares during the period. Finally, Oxford Asset Management LLP acquired a new stake in shares of Abeona Therapeutics in the 4th quarter worth $118,000. Hedge funds and other institutional investors own 80.56% of the company's stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.